文献速递冠心病血脂与心血管预防

炎症驱动慢性肾病患者的残余风险:CANTOS子研究

Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy.
PubMed 文献 · Eur Heart J · 2022-01-01

该研究基于CANTOS试验中9151例稳定他汀治疗的心梗后患者,按基线eGFR是否低于60 mL/min/1.73 m²分层,评估残余胆固醇风险和残余炎症风险对复发MACE及全因死亡的影响。结果显示,在eGFR低于60的患者中,hsCRP和IL-6显著预测复发MACE和全因死亡,而LDL-C和非HDL-C无显著预测作用;在eGFR不低于60的患者中,上述指标均与复发MACE正相关。

要点

  • 在eGFR低于60 mL/min/1.73 m²的他汀治疗心梗后患者中,hsCRP和IL-6升高显著预测复发MACE及全因死亡。
  • 在eGFR低于60的患者中,LDL-C和非HDL-C四分位升高与复发MACE无显著关联。
  • 在eGFR不低于60的患者中,hsCRP、IL-6、LDL-C和非HDL-C升高均与复发MACE正相关。

核心结论

  • 在已接受强化他汀治疗的肾功能受损动脉粥样硬化患者中,残余炎症风险对复发心血管事件风险起重要作用。

研究设计与样本

  • CANTOS试验子研究,纳入9151例稳定他汀治疗的心梗后患者,按基线eGFR是否低于60 mL/min/1.73 m²分层,随访至多5年(中位3.7年)。

主要发现

  • 在eGFR不低于60 mL/min/1.73 m²的患者中,hsCRP、IL-6、LDL-C和非HDL-C最高与最低四分位比较的复发MACE风险HR分别为1.45、2.48、1.64和1.68(均P<0.0001)。
  • 在eGFR低于60 mL/min/1.73 m²的患者中,hsCRP和IL-6最高与最低四分位比较的复发MACE风险HR分别为1.50(P=0.021)和1.84(P=0.048),而LDL-C和non-HDL-C无显著关联(HR分别为1.04,P=0.80和0.98,P=0.88)。
  • 在eGFR低于60 mL/min/1.73 m²的患者中,hsCRP(HR 1.77,P=0.0021)和IL-6(HR 2.15,P=0.015)显著预测全因死亡,而LDL-C(HR 0.91,P=0.56)和non-HDL-C(HR 0.85,P=0.31)无显著预测作用。
  • 按白蛋白与肌酐比值而非eGFR分层分析观察到类似效应。

临床怎么用

  • 对已接受强化他汀治疗的慢性肾病合并动脉粥样硬化患者,可考虑检测hsCRP和IL-6以评估残余炎症风险并辅助风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Hyperlipidaemia and inflammation jointly contribute to atherosclerotic disease. Yet, after the initiation of statin therapy, the relative contributions of these processes may differ in patient groups, such as those with and without impaired kidney function. METHODS AND RESULTS: Among 9151 stable statin-treated post-myocardial infarction patients participating in the CANTOS trial, the contributions of residual cholesterol risk and residual inflammatory risk were evaluated as determinants of recurrent major adverse cardiovascular events (MACE) and total mortality, stratified by baseline estimated glomerular filtration rate (eGFR) above or below 60 mL/min/1.73 m2 using the race agnostic CKD-EPI 2021 formula (all participants had eGFR > 30 mL/min/1.73 m2). Analyses of residual inflammatory risk focused on high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6) while analyses of residual cholesterol risk focused on LDL-cholesterol (LDL-C) and non-HDL-cholesterol (non-HDL-C). Participants were followed for a period of up to 5 years (median 3.7 years). Median baseline levels of LDL-C and hsCRP were 81 mg/dL and 4.2 mg/L. Among participants with eGFR ≥ 60 mL/min/1.73 m2, increasing quartiles of plasma hsCRP, IL-6, LDL-C, and non-HDL-C all positively associated with risks of recurrent MACE [hazard ratios (HR) comparing the top to bottom quartile for hsCRP 1.45; for IL-6 2.48; for LDL-C 1.64; and for non-HDL-C 1.68] (all P < 0.0001). By contrast, among those with eGFR < 60 mL/min/1.73 m2, increasing quartiles of hsCRP and IL-6 significantly predicted recurrent MACE [HR comparing the top to bottom quartile for hsCRP 1.50 (P = 0.021); for IL-6 1.84 (P = 0.048)], whereas increasing quartiles of LDL-C and non-HDL-C did not [HR comparing the top to bottom quartile for LDL-C 1.04 (P = 0.80); for non-HDL-C 0.98 (P = 0.88)]. The predictive utility of hsCRP and IL-6 in the setting of eGFR < 60 mL/min/1.73 m2 remained significant after adjustment for a wide range of potential confounding factors including age, sex, smoking status, blood pressure, body mass index, and diabetes. For the endpoint of total mortality, both hsCRP (HR 1.77, P = 0.0021) and IL-6 (HR 2.15, P = 0.015) were significant predictors among those with eGFR < 60 mL/min/1.73 m2, whereas LDL-C (HR 0.91, P = 0.56) and non-HDL-C (HR 0.85, P = 0.31) were not. Similar effects were observed in analyses stratified by the albumin to creatinine ratio rather than eGFR. CONCLUSION: Among atherosclerosis patients with impaired kidney function already aggressively treated with statin therapy, residual inflammatory risk plays a substantial role in determining the risk of recurrent cardiovascular events. These data have implications for risk stratification of individuals with chronic kidney disease and for the development of novel agents that target inflammatory processes in this high-risk group of patients. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: NCT01327846.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Ridker PM, Tuttle KR, Perkovic V, et al. Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy. Eur Heart J. 2022. PMID: 35943897. doi:10.1093/eurheartj/ehac444

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。